[{"orgOrder":0,"company":"Cochlear","sponsor":"University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"AUSTRALIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Cochlear","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cochlear \/ University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"Cochlear \/ University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research"},{"orgOrder":0,"company":"Ivano-Frankivsk National Medical University","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UKRAINE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"BNO 1030 Extract","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Ivano-Frankivsk National Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ivano-Frankivsk National Medical University \/ Bionorica SE","highestDevelopmentStatusID":"1","companyTruncated":"Ivano-Frankivsk National Medical University \/ Bionorica SE"},{"orgOrder":0,"company":"University Hospital Antwerp","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BELGIUM","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"University Hospital Antwerp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"University Hospital Antwerp \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Antwerp \/ Royal DSM"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Applied Biology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Safety Shot \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Safety Shot \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Safety Shot","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Jupiter Wellness","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Jupiter Wellness"},{"orgOrder":0,"company":"Keep Hearing, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Acemg","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Keep Hearing, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Keep Hearing, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Keep Hearing, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arthrospira maxima","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Creatine Monohydrate","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Powder","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Sestre Milosrdnice","sponsor":"JGL d.d","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CROATIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nasal Irrigation With Seawater Isotonic Solution","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"University Hospital Sestre Milosrdnice","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Spray","sponsorNew":"University Hospital Sestre Milosrdnice \/ Jadran Galenski laboratorij","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Sestre Milosrdnice \/ Jadran Galenski laboratorij"},{"orgOrder":0,"company":"Otovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OTOV101N","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Otovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Otovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pediatrica S.r.l","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Pediafl\u00f9","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Pediatrica S.r.l","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pediatrica S.r.l \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Pediatrica S.r.l \/ Tigermed"},{"orgOrder":0,"company":"CEN Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Plant Extract","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"CEN Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEN Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CEN Biotech \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae Vaccine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude Children \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Thickenup Gel Express","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Tianji Jishi Biotechnology","sponsor":"PhecdaMed | Yilai Shu","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TJ0113","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Hangzhou Tianji Jishi Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hangzhou Tianji Jishi Biotechnology \/ PhecdaMed | Yilai Shu","highestDevelopmentStatusID":"1","companyTruncated":"Hangzhou Tianji Jishi Biotechnology \/ PhecdaMed | Yilai Shu"},{"orgOrder":0,"company":"Hospital de Matar\u00f3","sponsor":"Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Hospital de Matar\u00f3","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de Matar\u00f3 \/ Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"Hospital de Matar\u00f3 \/ Nutricia Inc"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hangzhou Tianji Jishi Biotechnology

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Hangzhou Tianji Jishi Biotechnology

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : TJ0113 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Presbycusis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 10, 2025

                          Lead Product(s) : TJ0113

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : PhecdaMed | Yilai Shu

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : Arthrospira maxima is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hearing Loss, Sensorineural.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          May 30, 2025

                          Lead Product(s) : Arthrospira maxima

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Cochlear

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Cochlear

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Study Phase : Undisclosed

                          Sponsor : University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in clinical studies for the treatment of Hearing Loss.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : University of Iowa | LWB Consulting | Althea Anagnostopoulos Harrington | MV Clinical Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : This is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Deglutition Disorders.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 25, 2024

                          Lead Product(s) : Protein

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Keep Hearing, Inc.

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Keep Hearing, Inc.

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Acemg is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hearing Loss, Sensorineural.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          June 27, 2024

                          Lead Product(s) : Acemg

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Hospital de Mataró

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Hospital de Mataró

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Deglutition Disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 09, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Nutricia Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University Hospital Sestre Milosrdnice

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          University Hospital Sestre Milosrdnice

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Nasal Irrigation With Seawater Isotonic Solution is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Nasal Obstruction.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 17, 2023

                          Lead Product(s) : Nasal Irrigation With Seawater Isotonic Solution

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : JGL d.d

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Otovia Therapeutics

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Otovia Therapeutics

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : OTOV101N is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Hearing Loss, Sensorineural.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 13, 2023

                          Lead Product(s) : OTOV101N

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : Creatine Monohydrate is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Presbyphonia.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : Creatine Monohydrate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 for tinnitus, emergent symptoms lasting longer than 4 weeks since onset.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 06, 2022

                          Lead Product(s) : Pimozide

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Applied Biology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank